Clinical Trial Update: Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab for high-risk oral intraepithelial neoplasia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Oral Cavity
• Oral Intraepithelial Neoplasia

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia | Phase 2 | Status: COMPLETED | Results posted: 2025-10-23